1. Hsu, LY, Chia, PY, Lim, JF. The novel coronavirus (SARS-CoV-2) epidemic. Ann Acad Med Singap 2020; 49: 105–107.
Google Scholar | Crossref | Medline2. Lu, R, Zhao, X, Li, J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020; 395: 565–574.
Google Scholar | Crossref | Medline3. Hoque, MN, Chaudhury, A, Akanda, MAM, et al. Genomic diversity and evolution, diagnosis, prevention, and therapeutics of the pandemic COVID-19 disease. PeerJ 2020; 8: e9689.
Google Scholar | Crossref | Medline4. World Health Organization . WHO coronavirus disease (COVID-19) dashboard. WHO coronavirus disease (COVID-19) dashboard, https://covid19.who.int/ (2021, accessed 16 January 2021).
Google Scholar5. Gattinoni, L, Chiumello, D, Caironi, P, et al. COVID-19 pneumonia: different respiratory treatments for different phenotypes? Intensive Care Med 2020; 46: 1099–1102.
Google Scholar | Crossref | Medline6. Mullard, A. How COVID vaccines are being divvied up around the world. Nature. Epub ahead of print 30 November 2020. DOI: 10.1038/d41586-020-03370-6.
Google Scholar | Crossref | Medline7. Korang, SK, Juul, S, Nielsen, EE, et al. Vaccines to prevent COVID-19: a protocol for a living systematic review with network meta-analysis including individual patient data (The LIVING VACCINE Project). Syst Rev 2020; 9: 262.
Google Scholar | Crossref | Medline8. Baden, LR, El Sahly, HM, Essink, B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. Epub ahead of print 30 December 2020. DOI: 10.1056/NEJMoa2035389.
Google Scholar | Crossref9. Zhang, Y, Zeng, G, Pan, H, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. Epub ahead of print 17 November 2020. DOI: 10.1016/S1473-3099(20)30843-4.
Google Scholar | Crossref10. Our World in Data . COVID-19 vaccine doses administered per 100 people, https://ourworldindata.org/grapher/covid-vaccination-doses-per-capita (2021, accessed 16 January 2021).
Google Scholar11. Marano, G, Vaglio, S, Pupella, S, et al. Convalescent plasma: new evidence for an old therapeutic tool? Blood Transfus 2016; 14: 152–157.
Google Scholar | Medline12. Tanne, JH. Covid-19: FDA approves use of convalescent plasma to treat critically ill patients. BMJ 2020; 368: m1256.
Google Scholar | Crossref | Medline13. Murphy, M, Estcourt, L, Grant-Casey, J, et al. International survey of trials of convalescent plasma to treat COVID-19 infection. Transfus Med Rev 2020; 34: 151–157.
Google Scholar | Crossref | Medline14. Liu, STH, Lin, H-M, Baine, I, et al. Convalescent plasma treatment of severe COVID-19: a propensity score–matched control study. Nat Med 2020; 26: 1708–1713.
Google Scholar | Crossref | Medline15. Erkurt, MA, Sarici, A, Berber, İ, et al. Life-saving effect of convalescent plasma treatment in covid-19 disease: clinical trial from eastern Anatolia. Transfus Apher Sci 2020; 59: 102867.
Google Scholar | Crossref | Medline16. Abolghasemi, H, Eshghi, P, Cheraghali, AM, et al. Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: results of a multicenter clinical study. Transfus Apher Sci 2020; 59: 102875.
Google Scholar | Crossref | Medline17. Libster, R, Pérez Marc, G, Wappner, D, et al. Early high-titer plasma therapy to prevent severe Covid-19 in older adults. N Engl J Med 2021; 384: 610–618.
Google Scholar | Crossref | Medline18. Agarwal, A, Mukherjee, A, Kumar, G, et al. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID trial). BMJ 2020; 371: m3939.
Google Scholar | Crossref | Medline19. Li, L, Zhang, W, Hu, Y, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19. JAMA 2020; 324: 460.
Google Scholar | Crossref | Medline20. Moher, D, Liberati, A, Tetzlaff, J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6: e1000097.
Google Scholar | Crossref | Medline | ISI21. Sterne, JAC, Savović, J, Page, MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019; 366: l4898.
Google Scholar | Crossref | Medline22. Simonovich, VA, Burgos Pratx, LD, Scibona, P, et al. A randomized trial of convalescent plasma in Covid-19 severe pneumonia. N Engl J Med 2021; 384: 619–629.
Google Scholar | Crossref | Medline23. Royal College of Physicians . National Early Warning Score (NEWS) 2. RCP London, https://www.rcplondon.ac.uk/projects/outputs/national-early-warning-score-news-2 (2017, accessed 8 September 2020).
Google Scholar24. Marshall, JC, Murthy, S, Diaz, J, et al. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis 2020; 20: e192–e197.
Google Scholar | Crossref | Medline25. United Nations Office for the Coordination or Humanitarian Affairs . Epidemiological alert: recurring waves and outbreaks of COVID-19, https://reliefweb.int/report/world/epidemiological-alert-recurring-waves-and-outbreaks-covid-19-9-october-2020 (2020, accessed 14 January 2021).
Google Scholar26. Sarkar, S, Soni, KD, Khanna, P. Convalescent plasma is a clutch at straws in COVID-19 management! A systematic review and meta-analysis. J Med Virol 2021; 93: 1111–1118.
Google Scholar | Crossref | Medline27. Meher, BR, Padhy, BM, Das, S, et al. Effectiveness of convalescent plasma therapy in the treatment of moderate to severe COVID 19 patients: a systematic review and meta-analysis. J Assoc Physicians India 2020; 68: 35–43.
Google Scholar | Medline28. Shao, S, Wang, Y, Kang, H, et al. Effect of convalescent blood products for patients with severe acute respiratory infections of viral etiology: a systematic review and meta-analysis. Int J Infect Dis 2021; 102: 397–411.
Google Scholar | Crossref | Medline29. Wenjing, L, Yuanzheng, F, Li, J-Y, et al. Safety and efficacy of convalescent plasma therapy in severely and critically ill patients with COVID-19: a systematic review with meta-analysis. Aging (Albany NY). Epub ahead of print 16 November 2020. DOI: 10.18632/aging.202195.
Google Scholar | Crossref | Medline30. Bakhtawar, N, Usman, M, Khan, MMU. Convalescent plasma therapy and its effects on COVID-19 patient outcomes: a systematic review of current literature. Cureus. Epub ahead of print 3 August 2020. DOI: 10.7759/cureus.9535.
Google Scholar | Crossref31. Chai, KL, Valk, SJ, Piechotta, V, et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Cochrane Database Syst Rev. Epub ahead of print 12 October 2020. DOI: 10.1002/14651858.CD013600.pub3.
Google Scholar | Crossref32. Wang, Y, Huo, P, Dai, R, et al. Convalescent plasma may be a possible treatment for COVID-19: a systematic review. Int Immunopharmacol 2021; 91: 107262.
Google Scholar | Crossref | Medline33. Devasenapathy, N, Ye, Z, Loeb, M, et al. Efficacité et innocuité du plasma de convalescent en cas de forme grave de COVID-19, extrapolée de données relatives à d’autres formes graves d’infections respiratoires virales : revue systématique et méta-analyse. Can Med Assoc J 2020; 192: E1559–E1570.
Google Scholar | Crossref34. Zhu, T, Xu, A, Bai, X, et al. Effect of convalescent plasma and immunoglobulin on patients with severe acute respiratory syndrome: a systematic review. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue 2020; 32: 435–438.
Google Scholar | Medline35. Sun, M, Xu, Y, He, H, et al. A potentially effective treatment for COVID-19: a systematic review and meta-analysis of convalescent plasma therapy in treating severe infectious disease. Int J Infect Dis 2020; 98: 334–346.
Google Scholar | Crossref | Medline36. Zaffanello, M, Piacentini, G, Nosetti, L, et al. The use of convalescent plasma for pediatric patients with SARS-CoV-2: a systematic literature review. Transfus Apher Sci. Epub ahead of print 23 December 2020. DOI: 10.1016/j.transci.2020.103043.
Google Scholar | Crossref | Medline37. Maiztegui, J, Fernandez, N, De Damilano, A. Efficacy of immune plasma in treatment of Argentine Hemorrhagic fever and association between treatment and a late neurological syndrome. Lancet 1979; 314: 1216–1217.
Google Scholar | Crossref38. Gharbharan, A, Jordans, C, Geurtsvankessel, C, et al. Convalescent plasma for COVID-19: a multicenter, randomized clinical trial. medRxiv Prepr Serv, 2020. DOI: 10.1101/2020.08.26.20182444.
Google Scholar | Crossref39. Saverino, D. Hyper-immune/convalescent plasma: an old option and a valid strategy for treatment of COVID-19? Minerva Med. Epub ahead of print 14 May 2020. DOI: 10.23736/S0026-4806.20.06616-1.
Google Scholar | Crossref | Medline40. Abeldaño Zuñiga, RA, Coca, SM, Abeldaño, GF, et al. Clinical effectiveness of drugs in hospitalized patients with COVID-19: a systematic review and meta-analysis. Ther Adv Respir Dis 2021; 15: 175346662110072.
Google Scholar | SAGE Journals | ISI41. Laure, G, Viet-Thi, T, Elodie, P, et al. 14-Day survival among older adults with severe SARS-Cov2 infection treated with corticosteroid: a cohort study. Clin Microbiol Infect. Epub ahead of print 2 April 2021. DOI: 10.1016/j.cmi.2021.03.021.
Google Scholar | Crossref42. Wang, Y, Zhang, D, Du, G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2020; 395: 1569–1578.
Google Scholar | Crossref | Medline43. The World Bank . Different scenarios for global growth, in five charts, https://blogs.worldbank.org/developmenttalk/different-scenarios-global-growth-five-charts (2021, accessed 16 January 2021).
Google Scholar